These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33524538)

  • 21. [Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
    Ohkawa S
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():198-202. PubMed ID: 16457249
    [No Abstract]   [Full Text] [Related]  

  • 22. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
    Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
    Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
    [No Abstract]   [Full Text] [Related]  

  • 23. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
    Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pancreatic carcinoma: progress in therapy].
    Lordick F
    Krankenpfl J; 2004; 42(5-6):158-9. PubMed ID: 15527223
    [No Abstract]   [Full Text] [Related]  

  • 25. [IMRD therapy for patients with metastatic pancreas cancer].
    Yamashita K; Takahashi Y
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():219-22. PubMed ID: 16457254
    [No Abstract]   [Full Text] [Related]  

  • 26. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
    Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
    ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
    Andersson R; Aho U; Nilsson BI; Peters GJ; Pastor-Anglada M; Rasch W; Sandvold ML
    Scand J Gastroenterol; 2009; 44(7):782-6. PubMed ID: 19214867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemotherapy in pancreatic cancer].
    Láng I
    Orv Hetil; 2004 Feb; 145(5):239-42. PubMed ID: 15024936
    [No Abstract]   [Full Text] [Related]  

  • 29. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel advances in pancreatic cancer treatment.
    Vulfovich M; Rocha-Lima C
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):993-1002. PubMed ID: 18533808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 32. In focus: advanced pancreatic cancer.
    Kindler HL
    Clin Adv Hematol Oncol; 2005 May; 3(5):420-2. PubMed ID: 16167016
    [No Abstract]   [Full Text] [Related]  

  • 33. Gemcitabine-loaded microbubble system for ultrasound imaging and therapy.
    Delaney LJ; Eisenbrey JR; Brown D; Brody JR; Jimbo M; Oeffinger BE; Stanczak M; Forsberg F; Liu JB; Wheatley MA
    Acta Biomater; 2021 Aug; 130():385-394. PubMed ID: 34082100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro.
    Alibolandi M; Ramezani M; Abnous K; Hadizadeh F
    J Pharm Sci; 2016 May; 105(5):1741-1750. PubMed ID: 27039356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
    Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
    Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy.
    Bridges E; Harris AL
    Cancer Cell; 2015 Jan; 27(1):7-9. PubMed ID: 25584889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
    Yamauchi J; Kanai M; Matsumoto S; Nishimura T; Yazumi S; Kami K; Kawaguchi Y; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Fukushima M; Doi R; Chiba T
    Pancreas; 2008 Apr; 36(3):327-8. PubMed ID: 18362852
    [No Abstract]   [Full Text] [Related]  

  • 38. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
    Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
    Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer. Breaching the cancer fortress.
    Olson P; Hanahan D
    Science; 2009 Jun; 324(5933):1400-1. PubMed ID: 19520948
    [No Abstract]   [Full Text] [Related]  

  • 40. Gemcitabine plus cisplatin in advanced pancreatic cancer.
    McWilliams RR; Alberts SR
    J Clin Oncol; 2007 Mar; 25(9):1142; author reply 1142-3. PubMed ID: 17369580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.